Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Intangibles: 2022-2025

Historic Intangibles for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to $2.9 million.

  • InMed Pharmaceuticals' Intangibles changed negligibly% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $2.9 million for FY2025, which is negligibly% changed negligibly from last year.
  • According to the latest figures from FY2025, InMed Pharmaceuticals' Intangibles is $2.9 million, which was down 0.00% from $2.9 million recorded in FY2024.
  • In the past 5 years, InMed Pharmaceuticals' Intangibles registered a high of $2.9 million during FY2023, and its lowest value of $2.1 million during FY2022.
  • For the 3-year period, InMed Pharmaceuticals' Intangibles averaged around $2.9 million, with its median value being $2.9 million (2025).
  • Data for InMed Pharmaceuticals' Intangibles shows a peak YoY spiked of 38.81% (in 2023) over the last 5 years.
  • Yearly analysis of 4 years shows InMed Pharmaceuticals' Intangibles stood at $2.1 million in 2022, then surged by 38.81% to $2.9 million in 2023, then remained steady at $2.9 million in 2024, then remained steady at $2.9 million in 2025.